Introduction {#sec1-1}
============

Breast cancer is the most frequently diagnosed cancer among women, which contributed to 25 % of all cancer cases in women worldwide (Shiryazdi et al., 2015; Yazdi et al., 2015). A hereditary component accounts for 10-15% of all breast and ovarian cancer cases. It is estimated that 30% of hereditary breast cancer cases are due to mutations in one of the BRCA1 and BRCA2 genes (Forat-Yazdi et al., 2015; Neamatzadeh et al., 2015). Ovarian cancer is the fifth leading cause of cancer deaths occurring in women and leading cause of mortality from gynecologic cancer (Stewart et al., 2013). It is estimated that familial ovarian cancer accounts for 5-15% of the total cases of ovarian cancer (Lynch et al., 2009). It is known that family history is one of the most important risk factors in ovarian cancer development. A possible genetic contribution to both breast and ovarian cancer risk is indicated by the increased incidence of these cancers among women with a family history (National Comprehensive Cancer Network). The mechanism of breast and ovarian carcinogenesis is still not well understood (Yoneda et al., 2012). It has been reported that several potential genes (with low, medium and high penetrance) and combining with environmental factors may be important in the development of these malignancies (Xu et al., 2014; Yoneda et al., 2012).

The X-Ray Repair Cross-Complementing Group 2 (XRCC2) gene encodes a member of the Rad51 family of related proteins that maintains chromosome stability by participating in homologous recombination and repairs DNA damage. The XRCC2 and XRCC3 are two of the members of RAD51-related proteins (Michalska et al., 2016; Sobhan et al., 2017). The XRCC2 gene has roles in the homologous recombination repair (HRR) pathway of double-stranded DNA, which repairs chromosomal fragmentation, deletions and translocations (Kuschel et al., 2002). A significant number of single nucleotide polymorphisms (SNPs) have been identified in the XRCC2 gene such as rs3218536 (Arg188His), rs718282, rs3218384, rs3218550, rs3218408, rs2040639 and rs3218499 (Xu et al., 2014; Sarwar et al., 2016). Of these SNPs, XRCC2 rs3218536 polymorphism is caused by A to G transition in exon 3 and results in Arginine (Arg) in substitution of Histidine (His) at codon 188 of the protein. However, it is thought that the XRCC2 rs3218536 polymorphism associated with a lowered risk for breast cancer and epithelial ovarian cancer. To date, several studies have been conducted to evaluate the association of XRCC2 rs3218536 polymorphism with breast and ovarian cancer. However, the conclusions have been conflicting. Therefore, we performed the current meta-analysis to clarify the association between XRCC2 rs3218536 polymorphism with risk of breast and ovarian cancer.

Materials and Methods {#sec1-2}
=====================

Literature and Search Strategy {#sec2-1}
------------------------------

We have conducted a systematic literature search using the PubMed, Gene, Google scholar, Web of Science and EMBASE database to find studies assessing the association between XRCC2 rs3218536 polymorphism and two breast and ovarian cancer up to January 20, 2017. We sought publication with the following key words: ''breast cancer'', ''ovarian cancer'', ''X-Ray Repair Cross Complementing 2'', ''DNA repair protein XRCC2'', ''XRCC2'', ''rs3218536'', "single nucleotide polymorphism", "polymorphism", "SNP", "mutation", and "variation". In addition, we have identified related studies by hand screening of included studies. The search was limited to human studies were published only in English language.

Inclusion Criteria and Data Extraction {#sec2-2}
--------------------------------------

The studies included in the current meta-analysis meet the following criteria: (1) evaluates the associations between XRCC2 rs3218536 polymorphism and breast and ovarian cancer risk; (2) used case--control or prospective cohort design; and (3) containing at least genotype frequencies for estimating an odds ratio (OR) with 95% confidence interval (95% CI). In addition, the exclusion criteria were as the follows: (1) not conducted on human subjects, (2) not breast and ovarian cancer research (3) only included patients or healthy subjects, (4) duplicate of previous publications (completely or partially), and (5) above all, have not sufficient data about frequency of genotypes.

Data extraction {#sec2-3}
---------------

For each study, we have extracted carefully (two authors independently) the following data: First author, publication year, country of origin, ethnicity, number of cases and controls, and Hardy--Weinberg Equilibrium (HWE). Any disagreements were discussed and resolved through consensus with a third investigator. In this meta-analysis the subject's (cases and controls) ethnicities were categorized as Caucasian, Asian, or African.

Statistical analysis {#sec2-4}
--------------------

The strength of association was assessed by calculating the odds ratios and 95% confidence intervals and the Z-test was used to evaluate statistical significance with P-values less than 0.01 considered as statistically significant. Pooled ORs were estimated for five genetic contrast including allele (A vs. G), heterozygote (AG vs. GG), homozygote (AA vs. GG), dominant (AA+AG vs. GG) and recessive (AA vs. AG+GG) contrasts. In the current meta-analysis, the heterogeneity between studies was calculated by X2-based Q test and I2. The heterogeneity were considered significant when p value was less than 0.05 for the Q test or I2\>25% in I2 statistics. Moreover, a random effects model using the DerSimonian was utilized to calculate the OR and 95% CI for comparisons with moderate to high heterogeneity (P-value \> 0.1 and I2 \> 25%) (DerSimonian et al., 1986). Otherwise, a fixed-effects model using the Mantel--Haenszel method was used. Sensitivity analysis was performed by sequential omission of individual studies (leave-one-out analysis) for various genetic models in the overall population and for subgroup analysis by ethnicity and HWE status. We have evaluated publication bias graphically using the Begg's funnel plot and statistically using the method of Egger's linear regression test (Egger et al., 1997); P\<0.05 indicated that the result was statistically significant. We have used comprehensive meta-analysis (CMA) V2.0 software (Biostat, USA) to perform all the statistical analyses. Two-sided P values \< 0.05 were considered statistically significant.

Results {#sec1-3}
=======

Characteristics of the included studies {#sec2-5}
---------------------------------------

Based on the established search criteria, articles were retrieved for the association of XRCC2 rs3218536 polymorphism with breast and ovarian cancer susceptibility. Twenty publications (26 studies) met the inclusion criteria, the characteristics of which are showed in [Table 1](#T1){ref-type="table"} and [2](#T2){ref-type="table"}. Of these 20 publications, 16 publications (17 studies) with 5694 cases and 6450 controls evaluate the association of XRCC2 rs3218536 polymorphism with breast cancer risk. Two out of the 17 studies were published in Asians (Ding et al., 2014; Qureshi et al., 2014) and the others were in Caucasians (Rafii et al., 2002; Kuschel et al., 2002; Han et al., 2004; Webb et al., 2005; Millikan et al., 2005; Garcia-Closas et al., 2006; Brooks et al., 2008; Loizidou et al., 2008; Pooley et al., 2008; Silva et al., 2010; Jakubowska et al., 2010; Makowska et al., 2012; Smolarz et al., 2014; Shadrina et al., 2014). There were 15 studies of Caucasian descendants (USA, UK, Poland, Australia, Portugal, Russia and Cyprus) and 2 studies of East Asian descendants communities (China and Pakistan). In addition, of these 20 publications, 5 publications (9 case-control studies) with 4464 cases and 6353 controls for association between XRCC2 rs3218536 polymorphism and ovarian cancer. The populations came from different countries, including UK, Denmark, USA, Australia, Egypt and Poland. There were 8 studies (Auranen et al., 2005; Webb et al., 2005; Beesley et al., 2007; Michalska et al., 2016) of Caucasian descendants and 1 study (Mohamed et al., 2013) of African descendant. Genotype distributions in the controls of two studies for breast cancer (Loizidou et al., 2008; Silva et al., 2010) and two studies for ovarian cancer (Mohamed et al., 2013; Michalska et al., 2016) were not in agreement with HWE (p \< 0.05).

###### 

Characteristics of Studies Included in the Meta-Analysis of XRCC2 Rs3218536 Polymorphism and Breast Cancer

  First author                Country (Ethnicity)     Case/Control   Cases   Controls   HWE                                                   
  --------------------------- ----------------------- -------------- ------- ---------- ----- ------- ----- ------- ----- ----- ------- ----- ---------
  Rafii et al. 2002           UK (Caucasian)          519/398        431     82         6     944     94    351     45    2     747     49    0.669
  Kuschel et al. 2002         UK (Caucasian)          1725/1811      1,476   234        15    3,186   264   1,538   267   6     3,343   279   0.116
  Han et al. 2004             USA (Caucasian)         952/1237       811     134        7     1,756   148   1,066   165   6     2297    177   0.887
  Webb et al. 2005            Australia (Caucasian)   1447/783       1,251   187        9     2,689   205   675     101   7     1,451   115   0.144
  Millikan et al. 2005a       USA (Caucasian)         765/678        744     21         0     1,509   21    653     25    0     1331    25    0.624
  Millikan et al. 2005b       USA (Caucasian)         1268/1134      1,084   176        8     2,344   192   982     145   7     2,109   159   0.515
  Garcia-Closas et al. 2006   Poland (Caucasian)      1981/2280      1,763   212        6     3,738   224   1,983   281   16    4,247   313   0.085
  Brooks et al. 2008          USA (Caucasian)         602/602        515     83         4     1,113   91    519     78    5     1,116   88    0.283
  Loizidou et al. 2008        Cyprus (Caucasian)      1108/1177      972     135        1     2,079   137   999     177   34    2,175   245   \<0.001
  Pooley et al. 2008          UK (Caucasian)          4232/4384      3,590   610        32    7,790   674   3,639   711   34    7,989   779   0.91
  Silva et al. 2010           Portugal (Caucasian)    289/548        243     46         0     532     46    445     103   0     993     103   0.015
  Jakubowska et al. 2010      Poland (Caucasian)      314/290        272     42         0     586     42    254     36    0     544     36    0.259
  Makowska et al. 2012        Poland (Caucasian)      790/798        212     374        204   798     782   202     406   190   810     786   0.615
  Ding et al. 2014            China (Asian)           606/633        166     280        160   612     600   184     305   144   673     593   0.413
  Smolarz et al. 2014         Poland (Caucasian)      70/70          12      8          50    32      108   18      40    12    76      64    0.205
  Shadrina et al. 2014        Russia (Caucasian)      659/656        594     65         0     1253    65    587     67    2     1241    71    0.952
  Qureshi et al. 2014         Pakistan (Asian)        156/150        131     20         5     282     30    137     12    1     286     14    0.216

###### 

Characteristics of Studies Included in the Meta-Analysis of XRCC2 Rs3218536 Polymorphism and Ovarian Cancer

  First author            Country (Ethnicity)     Case/Control   Cases   Controls   HWE                                                       
  ----------------------- ----------------------- -------------- ------- ---------- ----- ----- ------ ------ ------ ----- ----- ------ ----- -------
  Auranen et al. 2005a    UK (Caucasian)          729            842     629        98    2     1356   102    704    129   9     1537   147   0.263
  Auranen et al. 2005b    Denmark (Caucasian)     944            404     260        54    1     574    56     331    68    5     730    78    0.481
  Auranen et al. 2005c    USA (Caucasian)         269            561     238        31    0     507    31     484    75    2     1043   79    0.614
  Auranen et al. 2005d    UK (Caucasian)          275            1811    251        23    1     525    25     1538   267   6     3343   279   0.116
  Webb et al. 2005a       Australia (Caucasian)   430            950     364        63    3     791    69     802    140   8     1744   156   0.492
  Webb et al. 2005b       Australia (Caucasian)   94             168     87         5     2     179    9      150    16    2     316    20    0.052
  Beesley et al. 2007     Australia (Caucasian)   923            817     799        117   7     1715   131    696    115   7     1507   129   0.356
  Mohamed et al. 2013     Egypt (African)         100            100     6          58    36    70     130    16     60    24    92     108   0.037
  Michalska et al. 2016   Poland (Caucasian)      700            700     120        80    500   320    1080   180    400   120   760    640   0.001

Meta-analysis {#sec2-6}
-------------

### Association of XRCC2 rs3218536 polymorphism and breast cancer {#sec3-1}

The meta-analysis of a possible association between XRCC2 rs3218536 polymorphism and breast cancer is summarized in [Table 3](#T3){ref-type="table"}. Based on the total study population, a strong association was found between of XRCC2 rs3218536 polymorphism and breast cancer under the heterozygote contrast (AG vs. GG: OR = 0.929, 95% CI = 0.873-0.987, p=0.018) in the overall population ([Figure 2E](#F1 F2){ref-type="fig"}). Considering the limited number of qualified studies in the Asian and other descendent population, the stratified analyses was only presented for Caucasians. In the subgroup analyses of ethnicity, the meta-analysis results indicated a strong association between the XRCC2 rs3218536 polymorphism and breast cancer susceptibility among Caucasians only under the heterozygote contrast (AG vs. GG: OR = 0.920, 95% CI = 0.861-0.980, p=0.009). Additionally, significant associations between the XRCC2 rs3218536 polymorphism and breast cancer under the recessive contrast (AG vs. GG: OR = 1.635, 95% C I = 1.109-2.413, p=0.013) was found according to the HWE.

###### 

Meta-Analysis of the Association of XRCC2 Rs3218536 Polymorphism and Breast Cancer

                 Genetic model   Type of model   Heterogeneity   Odds ratio   Publication Bias                           
  -------------- --------------- --------------- --------------- ------------ ------------------ ------- ------- ------- --
  Overall                                                                                                                
  A vs. G        Random          79.49           \<0.001         1.027        0.904-1.167        0.681   0.387   0.142   
  AG vs. GG      Fixed           30.49           0.113           0.929        0.873-0.987        0.018   0.592   0.412   
  AA vs. GG      Random          66.5            \<0.001         1.125        0.770-1.643        0.542   1       0.868   
  AA+AG vs. GG   Random          86.39           \<0.001         1.118        0.923-1.353        0.255   0.108   0.016   
  AA vs. AG+GG   Random          78.06           \<0.001         1.443        0.945-2.203        0.089   0.742   0.695   
  Caucasian                                                                                                              
  A vs. G        Random          79.49           \<0.001         0.998        0.872-1.143        0.979   0.552   0.216   
  AG vs. GG      Fixed           29.28           0.137           0.92         0.861-0.980        0.009   1       0.779   
  AA vs. GG      Random          69.57           \<0.001         1.038        0.647-1.665        0.878   0.631   0.76    
  AA+AG vs. GG   Random          87.52           \<0.001         1.098        0.892-1.352        0.377   0.165   0.033   
  AA vs. AG+GG   Random          80.92           \<0.001         1.354        0.774-2.371        0.289   0.45    0.856   
  HWE                                                                                                                    
  A vs. G        Random          73.54           \<0.001         1.077        0.956-1.213        0.225   0.165   0.033   
  AG vs. GG      Fixed           31.58           0.116           0.943        0.885-1.006        0.074   0.428   0.312   
  AA vs. GG      Random          54.02           0.01            1.232        0.892-1.701        0.206   0.582   0.555   
  AA+AG vs. GG   Random          86.57           \<0.001         1.196        0.973-1.471        0.089   0.047   0.009   
  AA vs. AG+GG   Random          73.75           \<0.001         1.635        1.109-2.413        0.013   0.854   0.28    

![Forest Plot For Association Of XRCC2 Rs3218536 Polymorphism With Breast And Ovarian Cancer Susceptibility. A: breast cancer (allele contrast: A vs. G), B: ovarian cancer (Recessive contrast: AA vs. AG+GG).](APJCP-18-1743-g001){#F1}

![Begg's Funnel Plots for Association of XRCC2 Rs3218536 Polymorphism with Breast and Ovarian Cancer for Publication Bias Test. Each Point Represents A Separate Study For The Indicated Association. A: breast cancer (dominant contrast: AA+AG vs. GG), B: ovarian cancer (dominant contrast: AA+AG vs. GG).](APJCP-18-1743-g002){#F2}

Association of XRCC2 rs3218536 polymorphism and ovarian cancer {#sec2-7}
--------------------------------------------------------------

The meta-analysis of a possible association between the XRCC2 rs3218536 polymorphism and risk of ovarian cancer is summarized in [Table 4](#T4){ref-type="table"}. The pooled analysis for XRCC2 rs3218536 polymorphism and risk of ovarian cancer involved 5 publications (9 case-control studies) with 4,464 cases and 6,353 controls. The pooled ORs revealed that XRCC2 rs3218536 polymorphism was associated with risk of ovarian cancer only under dominant genetic model (AA+AG vs. GG: OR = 0.725, 95% CI = 0.537-0.979, p=0.036) in the overall ([Table 4](#T4){ref-type="table"}). Stratification analysis by ethnicity showed significant association between XRCC2 rs3218536 polymorphism and ovarian cancer in Caucasian under heterozygote contrast (AG vs. GG: OR = 0.710, 95% CI = 0.517-0.975, p=0.034) and dominant contrast (AA+AG vs. GG: OR = 0.666, 95% CI = 0.502-0.884, p=0.005, [Table 2](#T2){ref-type="table"}, [Figure 2a](#F2){ref-type="fig"}). And we also observed association between this polymorphism and ovarian cancer according to the HWE under allele contrast (A vs. G: OR = 0.685, 95% CI = 0.496-0.947, p=0.034), heterozygote contrast (AG vs. GG: OR = 0.710, 95% CI = 0.517-0.975, p=0.034) and dominant contrast (AA+AG vs. GG: OR = 0.666, 95% CI = 0.502-0.884, p=0.005, [Table 2](#T2){ref-type="table"}, [Figure 2a](#F2){ref-type="fig"}).

###### 

Meta-Analysis of the Association of XRCC2 Rs3218536 Polymorphism and Ovarian Cancer

                 Genetic model   Type of model   Heterogeneity   Odds ratio   95% CI        POR     Publication Bias           
  -------------- --------------- --------------- --------------- ------------ ------------- ------- ------------------ ------- --
  Overall                                                                                                                      
  A vs. G        Random          97.33           \<0.001         0.922        0.491-1.732   0.801   1                  0.046   
  AG vs. GG      Random          82.27           \<0.001         0.767        0.555-1.059   0.107   0.916              0.798   
  AA vs. GG      Random          82.73           \<0.001         1.132        0.419-3.059   0.808   0.465              0.002   
  AA+AG vs. GG   Random          80.96           \<0.001         0.725        0.537-0.979   0.036   1                  0.825   
  AA vs. AG+GG   Random          92.22           \<0.001         0.992        0.294-3.348   0.99    0.916              0.002   
  Caucasian                                                                                                                    
  A vs. G        Random          97.66           \<0.001         0.862        0.429-1.730   0.675   1                  0.045   
  AG vs. GG      Random          82.15           \<0.001         0.71         0.517-0.975   0.034   0.386              0.685   
  AA vs. GG      Random          84.89           \<0.001         0.906        0.277-2.962   0.87    0.901              0.002   
  AA+AG vs. GG   Random          79.27           \<0.001         0.666        0.502-0.884   0.005   0.386              0.5     
  AA vs. AG+GG   Random          91.63           \<0.001         0.873        0.189-4.034   0.862   0.901              0.001   
  HWE                                                                                                                          
  A vs. G        Random          82.79           \<0.001         0.685        0.496-0.947   0.022   0.367              0.569   
  AG vs. GG      Fixed           12.14           0.337           0.855        0.745-0.981   0.026   0.229              0.241   
  AA vs. GG      Fixed           0               0.629           0.656        0.357-1.207   0.176   0.548              0.647   
  AA+AG vs. GG   Random          81.89           \<0.001         0.672        0.481-0.938   0.02    0.367              0.507   
  AA vs. AG+GG   Fixed           10.04           0.352           0.627        0.341-1.154   0.134   0.367              0.519   

Test of heterogeneity {#sec2-8}
---------------------

For XRCC2 rs3218536 polymorphism and breast cancer, when the data pooled a significant heterogeneity observed in allele (I^2^=79.49%, P~h~=\<0.001), homozygote (I^2^=66.50%, P~h~=0.042), dominant (I^2^=86.39%, P~h~=\<0.001) and recessive (I^2^=78.06%, P~h~=\<0.001) contrasts ([Table 3](#T3){ref-type="table"}). After subjects stratified by ethnicity and HWE status, the heterogeneity not disappeared obviously ([Table 3](#T3){ref-type="table"}). For XRCC2 rs3218536 polymorphism and ovarian cancer, when the data pooled a significant heterogeneity observed in allele (I^2^=97.33%, Ph=\<0.001), heterozygote (I^2^=82.27%, P~h~=\<0.001), homozygote (I^2^=82.73%, P~h~=\<0.001), dominant (I^2^=80.96%, P~h~=\<0.001) and recessive (I^2^=92.22%, P~h~=\<0.001) contrasts ([Table 4](#T4){ref-type="table"}). After subjects stratified by ethnicity and HWE status, the heterogeneity not disappeared obviously Caucasian. However, by HWE status the heterogeneity disappeared obviously in heterozygote (I^2^=12.14%, P~h~=0.337), homozygote (I^2^=0.00%, P~h~=0.629) and recessive (I^2^=10.04%, P~h~=0.352) contrasts ([Table 4](#T4){ref-type="table"}).

Publication bias {#sec2-9}
----------------

Both Begg's funnel plot and Egger's test were performed to assess the publication bias of literatures. The shapes of the funnel plots revealed no obvious asymmetry for association of XRCC2 rs3218536 polymorphism with breast cancer in the overall analyses ([Figure 2A](#F2){ref-type="fig"}). However, the results of Egger's regression test provided sufficient evidence for publication bias in dominant contrast (P~Begg's~=0.108, P~Eggers~=0.016), suggesting that there was obvious publication bias in the genetic contrast. In addition, the publication bias has seen in the meta-analysis XRCC2 rs3218536 polymorphism in Caucasians (dominant contrast: P~Begg's~=0.108, P~Eggers~=0.016) and by HWE status (allele contrast: P~Begg's~=0.165, P~Eggers~=0.033; dominant contrast: P~Begg's~=0.047, P~Eggers~=0.009). Moreover, the results of Egger's regression test provided evidence of publication bias for association of XRCC2 rs3218536 polymorphism with ovarian cancer in allele (P~Begg's~=1.000, P~Eggers~=0.033), homozygote (P~Begg's~=0.465, P~Eggers~=0.002) and recessive contrasts (P~Begg's~=0.916, P~Eggers~=0.002) in overall analysis. In addition, the publication bias has seen in the meta-analysis XRCC2 rs3218536 polymorphism and ovarian cancer in Caucasians (allele: P~Begg's~=1.000, P~Eggers~=0.045; homozygote: P~Begg's~=0.901, P~Eggers~=0.002 and recessive contrasts: P~Begg's~=0.901, P~Eggers~=0.001).

Discussion {#sec1-4}
==========

In this meta-analysis, we have evaluated the associations of XRCC2 rs3218536 polymorphism with breast and ovarian cancer susceptibility. To the best knowledge, our data suggested a significant association between the XRCC2 rs3218536 polymorphism and increased risk for breast cancer under heterozygote contrast. Additionally, the dominant contrast for the XRCC2 rs3218536 polymorphism indicated increased risk for OC.

Several meta-analyses have estimated the association between XRCC2 rs3218536 polymorphism and breast cancer risk (Yu et al., 2010; He et al., 2014; Kong et al., 2015; Zhang et al., 2016). He et al., (2014) in a meta-analysis of 45 case-control studies from 26 publications with 30868 cases and 38656 controls have evaluated XRCC2 rs3218536 polymorphism association with breast and ovarian cancer risk. According to their results, this polymorphism might be had different roles in development breast and ovarian cancer. Their findings not confer the association between XRCC2 rs3218536 polymorphism and breast cancer. While, they have showed this polymorphism might contribute to decreased ovarian cancer susceptibility. Actually, their findings suggested a protective role of the XRCC2 rs3218536 polymorphism in formation of ovarian cancer. Similarly to the He et al., (2014) results, in another meta-analysis of 16 studies involving 18,341 cases and 19,028 controls, Yu et al., (2010) not found evidence of a significant association between XRCC2 rs3218536 and breast cancer susceptibility in all five genetic contrasts. Also, in the recent meta-analysis by Kong et al., (2015) they have reported the same results to the two meta-analyses. However, inconsistent to the previous meta-analyses, we have found that the XRCC2 rs3218536 polymorphism positively confer the risk of development both breast cancer in the overall population and Caucasians. Interestingly, Zhang et al., (2016) in a meta-analysis of 15 case-control studies with 4,757 cases and 8,431 controls not found a significant association between XRCC2 rs3218536 polymorphism and ovarian cancer risk. In addition, in the stratified analyses by HWE status they have seen that rs3218536 polymorphism was associated with the decreased risk of ovarian cancer. However, in the current meta-analysis, we have found that this polymorphism significantly associated with risk of ovarian cancer in overall and by subgroup analysis in Caucasians and HWE status.

Many factors may contribute to the strong heterogeneity among overall analysis (Mehdinejad et al., 2017; Jafari Nedooshan et al., 2017). In the meta-analysis of XRCC2 rs3218536 polymorphism and breast cancer, the heterogeneity between studies was not significantly reduced in the subgroup analysis by the ethnicity and HWE, which indicating that the effect of XRCC2 rs3218536 in development breast cancer may not be modified by ethnicity and HWE. However, the heterogeneity between studies in the meta-analysis of XRCC2 rs3218536 polymorphism and ovarian cancer was significantly reduced by HWE status.

To the best knowledge, current meta-analysis is by far the most comprehensive and convicting on the association of the XRCC2 rs3218536 polymorphism with breast and ovarian cancer susceptibility to date. This meta-analysis has two strengths compared with previous meta-analysis as follow; first, in this meta-analysis, relatively all eligible studies with large sample sizes were included, which would decrease the risk of random error. Second, the quality of eligible publications included in meta-analysis was more satisfactory and met mostly the inclusion criteria. However, some limitations should be taken into consideration when explaining the results as follow: first, most of the studies included in the meta-analysis were performed in the Caucasian population, the limited number was from Asians (only two publications) and there was no relevant study from Africans. However, most subjects were from Caucasian, but limited to the UK, Poland and USA. Thus, to obtain more precise meta-analysis of XRCC2 rs3218536 polymorphism on breast and ovarian cancer susceptibility, additional studies with larger sample size and involving different ethnicities especially Asians and African are required. Second, because we have included only relevant published articles and written in English language in the meta-analysis, publication bias may have occurred, even though it was not found by making use of statistical tests. Third, the overall outcomes were based on individual unadjusted ORs without adjustment for other risk factors such as age, histological subtypes, clinical stages, menstrual status, environmental and other confounding lifestyle factors. Finally, this meta-analysis could not address the gene-gene and gene-environmental interactions in the association between XRCC2 rs3218536 polymorphism and risk of breast and ovarian cancer. Therefore, future studies that include detailed information on exposures to environmental factors to assess the possible gene-gene and gene-environment interactions in the association between XRCC2 rs3218536 polymorphism and risk of breast and ovarian cancer are required.

In summary, this systematic review and meta-analysis shows that the XRCC2 rs3218536 polymorphism was associated with breast and ovarian cancer susceptibility in overall population and Caucasians. According to the limitations listed above, Asian and African descendent studies should be similarly performed.
